A new "Seeking Alpha" article has emerged- I thought I saw another message board topic on this article but it now appears to be gone. Anyway, I think one of the important takeaways was the re-enforcement of the RTI Biologics partnership and how this can start to generate revenues for the Company in 2013.
Right now, I think Athersys is in the process of having its market capitalization corrected to a fairer value. The efforts of the Company to promote itself have paid off, IMHO, although as another poster suggested, the stock is still off the radar for most.
If the Company can actually start to generate significant revenues before we receive major trial info, we could be in for quite a run. You've got to love residual income for companies that have partnerships, which would be another plus once commercialization starts, assuming all goes well...
Yes I posted the article and they took it down. They meaning whoever controls this board through Yahoo Finance. Didn't claim it was mine or anything, just passing along printed available info. Whatever it WAS A GOOD article!
Whanton, the vast majority of stocks are "off the radar for most," as you said. But when it comes to microcap biotechs like Athersys, they're pretty much way beyond radar range. So as the stock is promoted by company PR, bloggers, conferences, positive news announcements, etc. there'll be growing investor interest because the story is so good. And that should boost the PPS going into the preliminary announcement this summer about indications from the ucerative colitis trial. And if those indications are positive, the media will be attracted and there will be a nice Athersys blip on the radar.
This has been on the radar as (5) distinct, new 13G's have been filed since October 2012. It's been under serious accumulation for past 6 months. Will go further as more individual and institutional investors understand what Athersys has the potential of achieving.
You make a good point: there's "off the radar" and "beyond radar range": when a company transfers from one category to another, there's huge potential with regard to where the stock can run. Assuming the Company is successful on some level, many people on the board will sell at 3 or 4, with many new buyers at that level looking for 10 or 20. In the meantime, there are a number of upcoming catalysts that can whipsaw the share price although until there are earnings, volatility will be high. This is my first biotech investment, so I'm out of my area in some regards, and as the Company doesn't really have earnings, I try and keep a close eye as best as I can, although it's obviously an extremely volatile situation. But if they can stabilize their burn rate through partnerships over the next year, I think we'll deserve a new plateau...